Mel Snyder: Beyond Sickle Cell Disease to the Future of Pediatric Genetics
Mel Snyder, Healthcare Commercialization and Strategy Advisor at ProClinica Inc., shared a post on LinkedIn:
“Now, more than 5000 American children with sickle cell disease can access a genetic cure for a disease that causes pain, organ damage, loss of school days, ans limited participation in sports and other childhood activities.
Possibly more important: The FDA’s action on Casgevy/Sickle-Cell Disease suggests a more liberal view of extending to pediatric patients other genetic cures until now reserved for adults.
Since the vast majority of genetic diseases first appear in infants, this FDA action may encourage more investment in public and private biopharmas working on agents for other genetic diseases first seen in childhood.”

Stay updated with Hemostasis Today.
-
Nov 17, 2026, 05:47Multidisciplinary Teams Kick Off SAHF MASAC ES 2026 with Pre-Symposium Workshops – South African Haemophilia Foundation
-
Nov 17, 2026, 05:41Boitumelo Malatji: South African Delegation Advances Advocacy Strategies at NNHF Southern Africa Workshop
-
Nov 17, 2026, 05:36Joining the PACTA Uganda Mental Health and Addiction Community Camp 2026 – Tackle Sickle Cell Africa
-
Nov 17, 2026, 05:30Nathan Connell: Women’s Hematology Summit 2027 to Address Hematologic Health Across the Lifespan
-
Nov 17, 2026, 05:25Mane Kurghinyan: Representing Armenia and HemAI Dynamics at the Falling Walls Lab Global Finale 2026
-
Nov 17, 2026, 01:27X. Long Zheng: Optimizing Treatment in Immune TTP
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH